Sleep onset insomnia in night owls is not merely a preference for late hours. It is a misalignment between internal circadian phase and desired sleep schedule. Research into peptide modulation of sleep architecture has grown, though much remains preclinical. Tesamorelin, a growth hormone-releasing hormone analogue, has documented effects on sleep fragmentation in specific populations. Pinealon, a short tripeptide, is investigated for circadian phase shifting. Their combined use for phase-advancing the circadian clock in delayed sleep phase disorder is not established. No content in this article should be interpreted as personalised medical guidance.

The Leningrad School and Circadian Peptides

Much of the foundational work on short peptides and biological rhythms comes from the laboratory of Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. Khavinson's group denoted Pinealon as a geroprotective and neuroprotective peptide. A 2019 review by Khavinson and colleagues summarised decades of work on peptide regulation of gene expression, including clock genes. The school's approach differs from Western pharmacology: it uses short peptides to normalise function rather than to block receptors. This is a crucial distinction. Pinealon is not a hypnotic. It is investigated as a modulator of circadian transcription.

Anisimov's laboratory, also in Saint Petersburg, extended this work into oncology and aging. A 2022 review from that group discussed melatonin and peptide interactions in circadian disruption. Their animal models of light-at-night exposure showed that certain peptides could partially restore rhythmicity of core body temperature and locomotor activity. The relevance to human night owls is indirect but suggestive. Except, and this matters, most of these investigations used intraperitoneal injection in rodents, not subcutaneous administration in humans.

Tesamorelin and Sleep Architecture

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. It is approved in some jurisdictions for reduction of visceral adipose tissue in HIV-associated lipodystrophy. Its effects on sleep have been secondary outcomes in several trials. A 2011 study in HIV patients reported improved sleep quality scores after six months of tesamorelin. A 2022 review of growth hormone secretagogues noted that tesamorelin increases slow-wave sleep in older adults. The mechanism is thought to involve growth hormone pulses during early sleep. Growth hormone release is coupled to slow-wave sleep. Increasing one may increase the other.

But sleep onset insomnia is not slow-wave sleep deficiency. Night owls often have normal or even increased slow-wave sleep once they fall asleep. The problem is the timing of sleep onset. Tesamorelin has not been shown to advance circadian phase. It may improve sleep continuity, but it does not shift the clock. Or maybe not. Some investigators have proposed that growth hormone secretagogues could indirectly influence circadian timing through metabolic feedback. A 2020 paper in Frontiers in Neuroscience discussed the bidirectional relationship between growth hormone and the suprachiasmatic nucleus. The evidence is preliminary. No human trial has tested tesamorelin for delayed sleep phase disorder.

Pinealon and Clock Gene Expression

Pinealon is the tripeptide Glu-Asp-Arg. It was developed at the Khavinson institute. In vitro studies show that Pinealon can increase expression of Per1 and Cry1 in neuronal cultures. A 2018 investigation in Bulletin of Experimental Biology and Medicine reported that Pinealon protected circadian gene expression in rat pinealocytes exposed to oxidative stress. The peptide appears to act as a bioregulator, not a direct agonist. It may enhance the cell's own capacity to maintain rhythmic transcription. This is a different mechanism from melatonin, which directly binds to MT1 and MT2 receptors.

Phase-advancing the circadian clock requires shifting the phase of the suprachiasmatic nucleus. Light is the most potent zeitgeber. Melatonin can phase-advance when taken in the evening. Pinealon has not been tested as a phase-shifting agent in humans. Its effects on clock genes in vitro are promising but not sufficient. A 2021 review from the Khavinson group noted that Pinealon's clinical applications remain limited to small trials in cognitive impairment and stress. No trial has examined Pinealon for sleep onset insomnia in night owls.

Tesamorelin and Pinealon: A Theoretical Combination

The rationale for combining tesamorelin and Pinealon rests on two distinct mechanisms. Tesamorelin may improve sleep continuity and slow-wave sleep. Pinealon may support circadian gene expression. Together, they could theoretically address both the quality and the timing of sleep. But this is speculation. No published study has administered both peptides to humans. No animal study has tested the combination for circadian phase shifting. The safety of combining a growth hormone secretagogue with a short peptide is unknown. Side-effect and adverse-event data for many peptides is sparse. Absence of reported harm does not equate to absence of risk.

Some researchers have proposed that growth hormone secretagogues could be used to treat circadian rhythm sleep disorders. A 2023 review in Sleep Medicine Reviews discussed the potential of ghrelin mimetics and GHRH analogues for shift work disorder. The authors noted that tesamorelin's long half-life makes it unsuitable for acute phase shifting. It may be more useful for stabilising sleep architecture once the clock is aligned. Pinealon's short half-life and low oral bioavailability further complicate clinical use. Most Pinealon studies use intranasal or subcutaneous administration. The combination would require careful timing and dosing, which have not been worked out.

Western Literature and Divergent Approaches

Western sleep medicine has largely ignored Pinealon. A PubMed search returns fewer than twenty papers. Most are from Russian-language journals. The Western approach to delayed sleep phase disorder relies on timed light exposure, melatonin, and cognitive behavioural therapy. A 2015 American Academy of Sleep Medicine guideline recommended these as first-line treatments. Peptides are not mentioned. This is not because peptides are ineffective. It is because the evidence base is too thin. Western regulatory agencies require randomised controlled trials. The Khavinson school has conducted few such trials. Their work is more observational and mechanistic.

There are exceptions. A 2019 trial of Epitalon, another Khavinson peptide, in elderly patients reported improved sleep quality. The trial was small and not placebo-controlled. A 2022 review of Epitalon for circadian disruption noted that the peptide may increase melatonin production in the pineal gland. This is relevant to night owls because endogenous melatonin onset is delayed in delayed sleep phase disorder. If Epitalon can advance melatonin onset, it could phase-advance the clock. But Epitalon is not Pinealon. They are different peptides with different sequences. Epitalon is a tetrapeptide, Ala-Glu-Asp-Gly. Pinealon is a tripeptide. Their mechanisms may overlap but are not identical.

Some Western researchers have begun to study growth hormone secretagogues for sleep. A 2022 study (PubMed) reported that tesamorelin improved sleep quality in patients with HIV and sleep disturbance. The effect was modest. No phase-shifting was observed. Another 2021 trial found that tesamorelin reduced sleep fragmentation in older adults with low growth hormone. These studies support a role for tesamorelin in sleep maintenance, not sleep onset. Night owls with sleep onset insomnia may not benefit from a drug that improves sleep continuity. They need a phase advance, not a sleep stabiliser.

Open Questions and Future Directions

The central open question is whether Pinealon can phase-advance the human circadian clock. No trial has tested this. A phase-advance protocol would require measuring dim-light melatonin onset before and after Pinealon administration. This is feasible but has not been done. A second question is whether tesamorelin's effects on slow-wave sleep could indirectly shift circadian phase. Slow-wave sleep is homeostatically regulated, not circadian. But the interaction between sleep homeostasis and circadian phase is complex. A third question is the safety of long-term peptide use. Growth hormone secretagogues can cause insulin resistance, joint pain, and fluid retention. Pinealon's long-term safety is unknown.

The combination of tesamorelin and Pinealon for sleep onset insomnia in night owls is not supported by current evidence. It is a hypothesis. The hypothesis is biologically plausible but unproven. Researchers interested in this area should consider a small, placebo-controlled trial of Pinealon alone for delayed sleep phase disorder. If Pinealon can advance dim-light melatonin onset, then adding tesamorelin might improve sleep quality during the shifted schedule. This is a logical next step. But it has not been taken.

For readers interested in related peptide research, this site has covered tesamorelin and Epitalon stacking for shift workers and Epitalon's role in circadian rhythm research. A separate discussion of tesamorelin for night-shift workers examines similar mechanisms. The evidence base remains thin, but the questions are worth asking.